China's updated ADR reporting rules to increase manufacturers' obligations
This article was originally published in SRA
Executive Summary
China's Ministry of Health has issued revised rules on the monitoring and reporting of adverse drug reactions1. The revised provisions will apply from 1 July and are likely to "significantly increase" the regulatory obligations of pharmaceutical manufacturers, according to legal experts at Sidley Austin2.